Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
ASH: Adcetris, Opdivo boost hopes for another ADC, PD-1 combo
Seagen trotted out new data suggesting its ADC Adcetris could work with BMS' PD-1 drug Opdivo in two classical Hodgkin lymphoma settings.
Angus Liu
Dec 10, 2023 7:30pm
ASH: Study digs into FDA adverse event record of BCMA therapies
Dec 9, 2023 11:54am
Along with CRISPR nod, FDA approves bluebird's SCD gene therapy
Dec 8, 2023 1:22pm
FDA signs off on Vertex, CRISPR's gene therapy for sickle cell
Dec 8, 2023 12:31pm
Merck, Eisai combo flops again, this time in endometrial cancer
Dec 8, 2023 12:27pm
BMS says goodbye to its top dealmaker Elizabeth Mily
Dec 8, 2023 11:25am
